Select language:  
1800 620 420
Close menu

Clinical trial for high-risk MDS tests new drug combination 

A Phase I investigator-driven clinical trial, which is ready to recruit its first participant, gives Australian patients with high-risk MDS access to two new oral drugs. 

  • Clinical trials
  • Myelodysplastic syndromes
  • Research
Read more

Supporting the advancement of science for Waldenström’s macroglobulinaemia

Research to further scientific knowledge of the cause and treatment of the uncommon type of blood cancer, Waldenström’s macroglobulinaemia (WM), is being co-funded by the Leukaemia Foundation. 

  • Other blood cancers
  • Research
Read more

Targeting DCAF as a novel treatment strategy for therapy-resistant myeloma 

Meet the research team developing a myeloma treatment with maximum efficacy and minimal side effects

  • Myeloma
Read more

Expert Series: Dr Michael Osborn discusses all aspects of acute lymphoblastic leukaemia

More than 80% of children newly diagnosed with acute lymphoblastic leukaemia (ALL) are successfully treated today – an achievement deemed by Dr Michael Osborn as “one of the true success stories of modern medicine”. 

  • Acute lymphoblastic leukaemia
  • Interviews with experts
  • Research
Read more

Planned clinical trial offers access to new therapy for rare acute leukaemia

Professor David Curtis has focused his research on searching for new ways to treat early T-cell precursor acute lymphoblastic leukaemia (ETP-ALL) which he describes as “a nasty type of leukaemia”. 

  • Acute lymphoblastic leukaemia
  • Clinical trials
  • Research
Read more

Expert Series: with Professor David Curtis

The ability to use haploidentical donors, or half matched donors, is the most important recent development in stem cell transplantation, says world leader in transplant research, Professor David Curtis. 

  • Acute lymphoblastic leukaemia
  • Interviews with experts
  • Research
Read more

AL amyloidosis Expert Series interview with Dr Hasib Sidiqi

We spoke to Dr Sidiqi about his specialising field of amyloidosis.

  • Amyloidosis
  • Interviews with experts
Read more

PBAC recommends daratumumab for newly diagnosed AL amyloidosis

Daratumumab (Darzalex®) could be the first ever therapy to be approved in Australia for AL amyloidosis.

  • Amyloidosis
  • Treatments and side-effects
Read more
Daratumumab

Expert Series: Prof. Wendy Erber – a tool predicting the potential progression of MPNs coming soon

Professor Wendy Erber and her research team in Western Australia are developing a monitoring tool they hope will identify MPN patients who will go on to develop leukaemia.

  • Interviews with experts
  • Myeloproliferative neoplasms
  • Research
Read more
Wendy Erber

Expert series interview: Dr Naranie Shanmuganathan on CML

The greatest unmet need in CML is the ability to predict outcomes at the time of diagnosis according to Dr Naranie Shanmuganathan, a consultant haematologist at Royal Adelaide Hospital and SA Pathology.

  • Chronic myeloid leukaemia
  • Interviews with experts
  • Research
Read more
Dr Naranie Shanmuganathan